Digest Network Come funziona
Network
/
Società
Go
Non verificato

Gossamer Bio, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

44 comunicati stampa

Guarda tutti i comunicati
11/09/2026
Finanza
Scienza
Legge/Diritto
Medicina - Varie
Associazioni/Professionisti
Cardiologia
Biotecnologia
Farmaceutica
Salute
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
09/09/2026
Finanza
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
04/09/2026
Web e Social Network
Fiere
Eventi
Salute
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Gossamer Bio to Present at Cantor Global Healthcare Conference
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
21/08/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
13/08/2026
Mercato azionario
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Cardiologia
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
27/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato del lavoro
Industria
Titoli e azioni
Biotecnologia
Sanità
Igiene alimentare
Salute
Farmaceutica
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
01/07/2026
Biotecnologia
Sanità
Farmaceutica
Salute
Titoli e azioni
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
17/06/2026
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
03/06/2026
Finanza
Biotecnologia
Farmaceutica
Salute
Cardiologia
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
02/06/2026
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0